Arvinas, Inc.
ARVNHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Arvinas, Inc. (ARVN) is listed under Biotechnology. Valued at $516.8M, ARVN is a small-cap name in its sector. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.
Market Cap
$516.8M
Beta
1.75
P/E (TTM)
—
P/E (Fwd)
-2.40
EPS (TTM)
$-3.18
EPS (Fwd)
$-3.33
ROE
-42.3%
ROA
-18.9%
Cash
$614.9M
Total Debt
$8.4M
Free CF
-$199.6M
52W Change
9.0%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $614.9M in cash comfortably exceeding the $8.4M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$199.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -42.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $131.4M to $262.6M.
With a beta above 1.5, ARVN tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Arvinas, Inc. and its sector.